SecBot SecBot

CTOR

CITIUS ONCOLOGY, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001851484 Biotech & Drug Discovery
$0.5957 +0.02 (+2.71%)
Oct 26 4:00 PM ET · prev $0.5800
Market cap
$65.0M
Micro cap
Median target
$4.00
+571% · range $4.00–4.00
1 year
−65.4%
from $1.72 · Oct 27
30 days
−42.2%
from $1.03
52-week range
$0.4930–1.75
−66% from high · low Mar 30
Avg volume 20D
118.7K
Oct 26 spike 871.0K
Short interest
289.7K
≈0.3% of shares · −43.1%
Days to cover
2.2
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 1 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/5
Strongest BEARISH Citius Oncology received a Nasdaq extension through April 19, 2027, to regain compliance with the $1.00…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.110 → −$0.190 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersCOVERING

    Short interest −43.1% to 289.7K shares. 2.2 days to cover, ≈0.3% of shares.

  • TrendDOWNTREND

    30% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED334,619$217.5K
OSAIC HOLDINGS, INC.NEAR_EXIT1,000$650.00
BANK OF AMERICA CORP /DE/DOUBLED3,835,160$2.4M
BlackRock, Inc.DOUBLED47,454$29.4K
UBS Group AGADD36,840$22.8K
VANGUARD GROUP INCDOUBLED596,997$597.0K
GEODE CAPITAL MANAGEMENT, LLCADD220,047$220.0K
NORTHERN TRUST CORPDOUBLED45,746$45.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Sep 2025
12-month targets · 1 analysts

Price is below the lowest target. Median implies +571%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 23, 2025Maxim Group
UPGRADE
UPGRADEBuy
May 23, 2025Maxim Group
DOWNGRADE
DOWNGRADEHold
Nov 27, 2024Maxim Group
INITIATE
INITIATEBuy
Aug 13, 2024EF Hutton
MAINTAIN
MAINTAINBuy

Earnings setup

Estimates
−$0.19
EPS estimate, this quarter
−73%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.19-$0.19–-$0.19+0.0%$5.8M
Next Q$0.00$0.00–$0.00—$14.3M
Current FY-$0.56-$0.56–-$0.56+6.7%$13.9M
Next FY$0.10$0.10–$0.10+0.0%$95.2M
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
Earnings
🔒 Fresh data, subscribers only
Aug 18, 2026
Earnings date
CTOR Q3 2026 Earnings Scheduled — 2026-08-18
Aug 12, 2026
Press release
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical…
Aug 10, 2026
Earnings date
CTOR Q3 2026 Earnings Scheduled — 2026-08-10
May 20, 2026
Earnings date
CTOR Q2 2026 Earnings Scheduled — 2026-05-20

Short side

FINRA· Sep 30, 2026
289,717
shares short
-43.1%
vs prior settlement
2.2
days to cover
≈0.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 26, 2026 Earnings
🔒 Fresh data, subscribers only
Oct 23, 2026 SEC
Citius Oncology received a Nasdaq extension through April 19, 2027, to regain compliance with the $1.00 minimum bid…
8-K — Impact 5/10
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
334,619 shares ($217.5K)
Jun 30, 2026 Inst.
OSAIC HOLDINGS, INC. — NEAR_EXIT
1,000 shares ($650.00)

SecBot reports

10 filings · 1 bullish · 3 bearish · 1 mixed · 5 neutral
All CTOR filing & press-release reports (10)